Clinical Trials
6 trialsNCT02289950 2021-09-02
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Eisai Inc.
Phase 2 Completed
NCT01218516 2020-08-20
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Morphotek
Phase 2 Completed
NCT01049061 2020-06-11
A Study of MORAb-003 in Patients With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT00318370 2015-09-09
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Morphotek
Phase 2 Completed
NCT01004380 2014-07-17
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Morphotek
Phase 1 Completed
NCT00428766 2013-11-06
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
Morphotek
Phase 1 Completed